vonoprazan
Selected indexed studies
- Vonoprazan: A New Potassium-Competitive Acid Blocker. (J Pharm Technol, 2023) [PMID:37323765]
- Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. (Gastroenterology, 2022) [PMID:35679950]
- Vonoprazan: A Review in Helicobacter pylori Infection. (Drugs, 2024) [PMID:38388872]
_Worker-drafted node — pending editorial review._
Connections
vonoprazan is a side effect of
Sources
- Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. (2023) pubmed
- Vonoprazan: A New Potassium-Competitive Acid Blocker. (2023) pubmed
- Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. (2022) pubmed
- Vonoprazan: A Review in Helicobacter pylori Infection. (2024) pubmed
- A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease. (2024) pubmed
- Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. (2024) pubmed
- The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. (2016) pubmed
- Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease. (2025) pubmed
- Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis. (2024) pubmed
- Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults. (2024) pubmed